SCHEMBL5060669

SCHEMBL5060669

COc1ccc(C(C(N)=S)c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.53
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
EPHX1 P07099 1/20 0.46
CA4 P22748 1/20 0.45
KLK7 P49862 2/20 0.44
PBRM1 Q86U86 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LTA4H P09960 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062194 0.93 CA1 (0.46) CYP1A2CYP2C19ALDH1A1L3MBTL1MAPT
SCHEMBL5052358 0.82 CTSD (0.46) ALDH1A1HSD17B10L3MBTL1
SCHEMBL4493891 0.82 ACP3 (0.57) ACP3CNR1CNR2ALDH1A1HSD17B10
SCHEMBL5056703 0.80 AHR (0.48) CNR1CNR2CYP1A2ALDH1A1NPSR1
SCHEMBL1716394 0.78 ACP3 (0.61) ACP3CNR1CNR2ALDH1A1HSD17B10
SCHEMBL6504793 0.78 ACP3 (0.61) ACP3CNR1CNR2ALDH1A1HSD17B10
SCHEMBL6755554 0.76 ACP3 (0.59) ACP3CNR1CNR2ALDH1A1HSD17B10
SCHEMBL5056427 0.76 IDO1 (0.50) CNR1CNR2CYP1A2CYP2C19ALDH1A1
SCHEMBL5056592 0.76 EPHX1 (0.41) ALDH1A1NPSR1EPHX1KLK7NPC1
SCHEMBL28833357 0.75 KLK7 (0.62) ACP3CNR1CNR2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119456-A1 Substituted Thiazoleacetic Acid as Crth2 Ligands 7TM PHARMA A/S (DK) 2008-05-22 US disclosed
US-20080119456-A1 Substituted Thiazoleacetic Acid as Crth2 Ligands 7TM PHARMA A/S (DK) 2008-05-22 US disclosed
US-20080119456-A1 Substituted Thiazoleacetic Acid as Crth2 Ligands 7TM PHARMA A/S (DK) 2008-05-22 US disclosed
EP-1758874-A1 SUBSTITUTED THIAZOLEACETIC ACIDS AS CRTH2 LIGANDS 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005116001-A1 SUBSTITUTED THIAZOLEACETIC AS CRTH2 LIGANDS 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119456-A1 Substituted Thiazoleacetic Acid as Crth2 Ligands HRH1, HRH2, HRH3 ACP3 3228/4885CNR1 198/4885CNR2 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.